| Literature DB >> 1731871 |
B J Stockman1, N R Nirmala, G Wagner, T J Delcamp, M T DeYarman, J H Freisheim.
Abstract
Dihydrofolate reductase is an intracellular target enzyme for folate antagonists, including the anticancer drug methotrexate. In order to design novel drugs with altered binding properties, a detailed description of protein-drug interactions in solution is desirable to understand the specificity of drug binding. As a first step in this process, heteronuclear three-dimensional NMR spectroscopy has been used to make sequential resonance assignments for more than 90% of the residues in human dihydrofolate reductase complexed with methotrexate. Uniform enrichment of the 21.5-kDa protein with 15N was required to obtain the resonance assignments via heteronuclear 3D NMR spectroscopy since homonuclear 2D spectra did not provide sufficient 1H resonance dispersion. Medium- and long-range NOE's have been used to characterize the secondary structure of the binary ligand-enzyme complex in solution.Entities:
Mesh:
Substances:
Year: 1992 PMID: 1731871 DOI: 10.1021/bi00116a031
Source DB: PubMed Journal: Biochemistry ISSN: 0006-2960 Impact factor: 3.162